Efficacy and safety of neoadjuvant therapy in gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis.
J Cancer Res Ther
; 20(2): 633-641, 2024 Apr 01.
Article
in En
| MEDLINE
| ID: mdl-38687934
ABSTRACT
OBJECTIVE:
To determine the effectiveness and safety of neoadjuvant therapy in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) and provide evidence-based suggestions for clinical treatment.METHODS:
The Cochrane Library, Embase, PubMed, and Web of Science were searched for articles published that analyzed the effectiveness and safety of GEP-NEN-targeted neoadjuvant therapy before March 2023. A confidence interval (CI) of 95%, a subgroup analysis, heterogeneity, and effect size (ES) were analyzed, and a meta-analysis of the literature was performed using the Stata BE17 software.RESULTS:
A total of 417 patients from 13 studies were included in this meta-analysis. The primary variables comprised the objective response rate (ORR), disease control rate (DCR), surgical resection rate, and R0 resection rate with ES values of 0.42 (95% CI 0.25-0.60), 0.96 (95% CI 0.93-0.99), 0.67 (95% CI 0.50-0.84), and 0.60 (95% CI 0.54-0.67), respectively. The secondary variables were the incidence rates of treatment-related adverse events (TRAEs), Grade 3 or higher TRAEs, and surgical complications with ES values of 0.29 (95% CI -0.03-0.21), 0.13 (95% CI -0.07-0.33), and 0.35 (95% CI 0.27-0.44), respectively.CONCLUSION:
Neoadjuvant therapy is an effective and safe treatment method for GEP-NENs. However, further studies are required to determine the optimal regimen for this therapy in these tumors.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pancreatic Neoplasms
/
Stomach Neoplasms
/
Neuroendocrine Tumors
/
Neoadjuvant Therapy
/
Intestinal Neoplasms
Limits:
Humans
Language:
En
Journal:
J Cancer Res Ther
Journal subject:
NEOPLASIAS
/
TERAPEUTICA
Year:
2024
Type:
Article
Affiliation country:
China